



London Genetics' third pharmacogenetic conference is attracting a wide range of high calibre speakers

London, UK, June 9 2011 – London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that its third annual pharmacogenetic conference will feature top-level presentations from players in all parts of the healthcare chain. To be held on 8-9th November 2011¹, in Windsor, UK, the theme for this year conference is 'Stratified Medicine: Making It Happen'. Topical issues will be discussed and debated with presentations from academia, the FDA, EMA, AstraZeneca, Novartis, Quintiles, Medco and the Wolfson Centre for Personalised Medicine, UK.

The conference is focused on how stratified medicine is affecting a range of activities, from reimbursement, prescribing and regulatory approval, to study design, use of biomarkers, data interpretation and the co-development of drugs and diagnostics. Consideration will also be given to some of the ethical issues, with a discussion from Professor Jonathan Wolff, member of the Nuffield Council on Bioethics Working Party for its recent report, 'Medical profiling and online medicine: the ethics of 'personalised healthcare' in a consumer age'².

Dr Elizabeth Foot, CEO of London Genetics, said, "We are delighted at how the agenda for London Genetics' third annual pharmacogenetic conference is developing, and are looking forward to hearing about the latest thinking in this rapidly evolving area. There was very positive feedback on the quality of the talks and interactions at last year's conference, and we expect the 2011 event to be just as successful for London Genetics, which has recently signed a research collaboration with an undisclosed pharmaceutical company".

¹ London Genetics 3rd Annual Pharmacogenetic Conference, 'Stratified Medicine: Making It Happen', 8-9th November 2011, Cumberland Lodge, Windsor, UK. For more details on the agenda and conference, please go to www.londongenetics.com

² 'Medical profiling and online medicine: the ethics of 'personalised healthcare' in a consumer age', Nuffield Council on Bioethics, October 12th 2010

Notes to Editors:

About London Genetics

London Genetics Limited (LGL), a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources. The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise, based on its access to 3,000 academic groups with a £650m annual research spend. Recent deals include a partnership with Diaceutics to accelerate biomarker development in the biopharmaceutical industry, and a cancer vaccine collaboration with Astrimmune. LGL is based in central London and has ISO 9001 accreditation. For further information, please go to www.londongenetics.com.

**For further information on London Genetics,
the conference or sponsorship opportunities please contact:**

London Genetics Ltd
271 Regent Street
London W1B 2ES
United Kingdom

Elizabeth Foot CEO
+ 44 (0) 20 7927 8330

Emma Palmer Foster
Strategic Communications Consultant
T + 44 (0) 7880 787185
E communications@londongenetics.com

